(Q34617897)

3 August 2017

title

Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? (English)

1 reference

3 August 2017

1 reference

cardiovascular disease

1 reference

1 reference

2

A James O'Malley

1 reference

3 August 2017

3

Nancy L Keating

1 reference

3 August 2017

Matthew R Smith

1

1 reference

3 August 2017

publication date

1 June 2008

1 reference

3 August 2017

1 reference

3 August 2017

volume

101

1 reference

3 August 2017

issue

11

1 reference

3 August 2017

page(s)

1335-1336

1 reference

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Metabolic syndrome: a solution in search of a problem

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

7 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07707.X

Changes in body composition during androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07707.X

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07707.X

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07707.X

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07707.X

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047398

Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18454791

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18454791

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Diagnosis and classification of diabetes mellitus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18454791

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1464-410X.2008.07707.X

1 reference

3 August 2017

1 reference

3 August 2017

1 reference